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a b s t r a c t 
This work addresses the multi-objective optimisation of manufacturing strategies of monoclonal antibod- 
ies under uncertainty. The chromatography sequencing and column sizing strategies, including resin at 
each chromatography step, number of columns, column diameters and bed heights, and number of cycles 
per batch, are optimised. The objective functions simultaneously minimise the cost of goods per gram 
and maximise the impurity reduction ability of the puriﬁcation process. Three parameters are treated as 
uncertainties, including bioreactor titre, and chromatography yield and capability to remove impurities. 
Using chance constraint programming techniques, a multi-objective mixed integer optimisation model 
is proposed. Adapting both ε-constraint method and Dinkelbach’s algorithm, an iterative solution ap- 
proach is developed for Pareto-optimal solutions. The proposed model and approach are applied to an 
industrially-relevant example, demonstrating the beneﬁts of the proposed model through Monte Carlo 
simulation. The sensitivity analysis of the conﬁdence levels used in the chance constraints of the pro- 
posed model is also conducted. 
© 2018 The Authors. Published by Elsevier Ltd. 













































The market of biopharmaceutical products is currently in a fast-
evelopment stage, in which the sales of monoclonal antibodies
mAbs) products, important biopharmaceutical drugs for the treat-
ent of cancer, autoimmune diseases, cardiovascular disease, etc.,
ave grown rapidly. There were approximately $90 billion global
ales in 2015, representing about 58% of the sales of all biophar-
aceuticals. It is expected that the worldwide sales will increase
o $110 billion by 2018 and $150 billion by 2021 ( Levine and
ooney, 2017 ). In the manufacturing processes of the mAb prod-
cts, chromatography operations in the downstream processing
DSP) are critical steps, which not only represent a large proportion
f the total manufacturing cost, but also play an important role in
he determination of the purity of ﬁnal products. Thus, it is critical
o identify the chromatography puriﬁcation process in the biophar-
aceutical manufacturing processes to produce cost-effective and
eliable high-purity biopharmaceutical drugs. 
Optimisation-based approaches exist in the literature for the
ptimal decision-making on downstream puriﬁcation processes.
he optimal synthesis of protein puriﬁcation processes was ad-∗ Corresponding author. 






098-1354/© 2018 The Authors. Published by Elsevier Ltd. This is an open access article uressed by developing mixed integer programming models and
olution approaches ( Vassquez-Alvarez et al., 2001; Simeonidis
t al., 2005; Natali et al., 2009; Polykarpou et al., 2011 ). A meta-
euristic optimisation approach with genetic algorithms was pro-
osed and applied to the production of mAbs to optimise pu-
iﬁcation sequences and chromatography column sizing strategies
 Simaria et al., 2012 ). Mixed integer optimisation models were also
roposed to determine the optimal development of bioprocesses,
sing a hybrid simulation-optimisation decomposition algorithm
or solution ( Brunet et al., 2012 ). Mixed integer programming tech-
iques were applied for the optimal chromatography column siz-
ng decisions in mAb manufacturing with different facility con-
gurations, to minimise the cost of goods per gram (COG/g) ( Liu
t al., 2013a,b ). The same authors further extended these mod-
ls to integrate both chromatography sequencing and column siz-
ng decisions using mixed integer linear fractional programming
MILFP), where Dinkelbach’s algorithm was adapted for solution
pproach ( Liu et al., 2014, 2015 ). Integrated decision tools com-
ining bioprocess economics and optimisation were developed for
he most cost-effective process ﬂowsheets in allogeneic cell ther-
py manufacturing ( Simaria et al., 2014; Hassan et al., 2015 ). Re-
ently, another approach for the optimisation of biopharmaceuti-
al downstream processes was developed by integrating detailed
echanistic models and artiﬁcial neural networks to maximise thender the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 




s downstream step 
Sets 
CS set of chromatography steps including capture, inter- 
mediate puriﬁcation, polishing 
R s set of resins suitable to chromatography step s 
Parameters 
A l s conﬁdence level in chance constraint for LRV at chro- 
matography step s 
A t conﬁdence level in chance constraint for titre 
A 
y 
s conﬁdence level in chance constraint for yield at chro- 
matography step s 
brv bioreactor volume, L 
cy sr yield of resin r at chromatography step s 
cyd l s lower bound of triangular distribution of yield devia- 
tion at chromatography step s 
cyd 
p 
s peak of triangular distribution of yield deviation at 
chromatography step s 
cyd u s upper bound of triangular distribution of yield devia- 
tion at chromatography step s 
dem annual demand, g 
f parameter in Dinkelbach’s algorithm representing fac- 
tion from previous iteration 
lrv sr LRV of resin r at chromatography step s 
lrv d l s lower bound of triangular distribution of LRV deviation 
at chromatography step s 
lrv d p s peak of triangular distribution of LRV deviation at 
chromatography step s 
lrv d u s upper bound of triangular distribution of LRV devia- 
tion at chromatography step s 
maxbn maximum number of batches 
ncy s yield at non-chromatography step s 
titre upstream bioreactor titre, g/L 
titre l lower limit of triangular distribution of upstream 
bioreactor titre, g/L 
titre p peak of triangular distribution of upstream bioreactor 
titre, g/L 
titre u upper bound of triangular distribution of upstream 
bioreactor titre, g/L 
TLRV min minimum required total LRV of the process 
TLRV U upper bound of total LRV of the process 
α bioreactor working volume ratio 
δ parameter in Dinkelbach’s algorithm representing tol- 
erance of objective function 
TLRV incremental step of total LRV of the process 
σ batch success rate 
 triangular cumulative distribution function of uncer- 
tain titre 
¯s triangular cumulative distribution function of uncer- 
tain resin yield deviation 
˜ s triangular cumulative distribution function of uncer- 
tain resin LRV deviation 
Continuous Variables 
AP annual product output, g 
COG annual cost of goods, £
LRV s LRV at chromatography step s 
M 0 initial product mass entering downstream processes 
per batch, g 
M s product mass per batch after step s , g 
OBJ 1 objective 1: COG/g 
OBJ 2 objective 2: total LRV 
Binary Variables 
U sr 1 if resin r is selected at chromatography step s ; 0 oth- 
erwise 
Auxiliary Variables 

















































t  yield of a process with three different chromatographic columns
( Pirrung et al., 2017 ). 
In addition, dealing with uncertainty is also an important is-
sue investigated in the literature on the optimisation of biophar-
maceutical manufacturing process, which is sensitive to uncertain
process parameters. The cost-effective equipment sizing strategies
of a real puriﬁcation process were addressed and a combinatorial
closed-loop optimisation problem was formulated and solved by
evolutionary algorithm, considering uncertain titre ( Allmendinger
et al., 2012, 2014a ). An optimisation framework was developed to
address the integrated optimisation of both upstream processing
(USP) and DSP of the mAb manufacturing, including bioreactor siz-
ing and chromatography sequencing and column sizing strategies,
under uncertainties in titre and chromatography yield. A chance
constrained programming (CCP) based mixed integer linear pro-
gramming (MILP) model was developed to tackle the uncertain-
ties there ( Liu et al., 2016 ). A Markov decision model was devel-
oped to identify the optimal condition-based bioreactor harvesting
policies, and the IgG 1 antibody production was investigated as a
case study ( Martagan et al., 2016 ). Ensemble modelling approach
was used to account for uncertainties in bioprocess optimisation
involving maximisation of the lower conﬁdence bound of the de-
sired bioprocess objective, using a mean-standard deviation util-
ity function, and was applied to a mAb batch production problem
( Liu and Gunawan, 2017 ). An optimisation framework, including aarkov decision model and state space structural analysis, was de-
eloped to deal with the trade-offs between yield and purity, start-
ng material uncertainties, puriﬁcation capability limitations, and
nterlinked decisions involving multiple puriﬁcation steps for engi-
eered proteins ( Martagan et al., 2018 ). 
All above works considered only single objective for optimisa-
ion, while in the real practice, there is more than one criterion to
easure the performance of manufacturing processes, which need
o be taken into account simultaneously when optimising the rel-
vant strategies, in order to achieve a balance among them. An
ptimisation framework with an evolutionary multi-objective op-
imisation algorithm was developed to consider multiple objec-
ives, including COG/g, robustness in COG/g, and impurity removal
apabilities, in the optimisation of mAb manufacturing process
 Allmendinger et al., 2014b ) Another decision-making framework
n rapid resin selection in biopharmaceutical puriﬁcation process
evelopment considered both yield of puriﬁcation process and pu-
ity of the target protein as objective functions, which were op-
imised by a mathematical programming model ( Liu et al., 2017 ).
ecently, a deterministic multi-objective optimisation model of a
iopharmaceutical manufacturing process was developed to opti-
ise both the cost and impurity removal capabilities of the puriﬁ-
ation process ( Liu and Papageorgiou, 2018 ). 
In this work, the model in Liu et al. (2014) is ex-
ended to address the multi-objective optimisation of bio-
S. Liu, L.G. Papageorgiou / Computers and Chemical Engineering 119 (2018) 383–393 385 

















































































pharmaceutical manufacturing processes under uncertainty. 
oth chromatography sequencing and column sizing strate-
ies of a mAb puriﬁcation process are determined in or-
er to achieve optimal COG/g and impurity removal ca-
ability at the DSP. Uncertainties in titre, chromatography
esin yield and impurity reduction ability are taken into
ccount, which have a signiﬁcant impact on the economic
nd production eﬃciency of the process, respectively. A CCP-based
ulti-objective mixed integer optimisation model is proposed
o handle the uncertainties, and eﬃcient solution approaches
re developed for Pareto-optimal solutions. To the best of our
nowledge, it is the ﬁrst attempt in the literature to develop
athematical programming-based models to solve multi-objective
ptimisation problems of biopharmaceutical manufacturing under
ncertainty. 
The remaining of this paper is organised as follows:
ection 2 describes the multi-objective optimisation problem.
he mathematical formulation of the proposed optimisation model
s given in Section 3 , followed by the proposed solution approach
n Section 4 . Section 5 presents an industrially-relevant example,
nd the computational results of optimisation and simulation are
hown and discussed in Section 6 . Finally, the concluding remarks
re drawn in Section 7 . 
. Problem statement 
In this work, a multi-objective optimisation problem of the mAb
anufacturing strategies, including the chromatography sequenc-
ng and column sizing strategies in the DSP, under uncertainty are
ddressed, to optimise both COG/g and impurity removal capability
f a mAb puriﬁcation process illustrated in Fig. 1 . In this process,
fter mammalian cells cultured in bioreactors at the USP, the mAb
s recovered, puriﬁed and cleared from potential viruses and impu-
ities in the DSP with three packed-bed chromatography steps for
apture, intermediate puriﬁcation and polishing, respectively. 
In each chromatography step, the resin is determined among
 number of suitable candidates, which are categorised in to dif-
erent types. It is assumed that at most one resin is allowed to
e selected from the candidates in each type into the sequence to
tilities the orthogonal separation mechanisms. Besides the chro-
atography sequencing decisions for resin selection, chromatogra-
hy column sizing strategies are also to be determined, including
he bed heights, diameters, number of chromatography columns,
s well as the number of running cycles per batch. The optimal
ecisions are chosen from a set of given discrete candidate values. 
Similar to the previous work ( Liu et al., 2013a,b, 2014, 2015 ), the
OG/g, which is equal to the annual total cost of goods (COG) di-
ided by the annual total output, is aimed to be minimised in this
ork. In addition, the impurity removal capability of the puriﬁca-
ion process is maximised as another objective function. Therefore, bi-objective optimisation problem is considered in this work.
o model the impurity removal capability, the host cell proteins
HCPs), produced or encoded by the organisms and unrelated to
he intended mAb product, are investigated as the critical impu-
ity in this work, and must be removed during DSP ( Levy et al.,
014 ), due to their antigenic effects in patients. Each candidate
esin’s logarithmic removal value (LRV) of HCPs is given, a measure
f the resin’s HCPs removal capability deﬁned as the logarithm of
he ratio of concentrations of HCPs in the outﬂow and inﬂow of
he resin. The total LRV of the process is the summation of LRVs
f all resins selected in the process, and therefore affected by the
hromatography sequencing strategies. 
The key parameters in this problem, bioreactor titre and the
hromatography yield and LRV of each resin, are associated with
ncertainty, due to the ﬂuctuations in USP and sensitivity of op-
rating conditions. In this work, the above mentioned three uncer-
ain parameters are assumed to follow triangular probability distri-
utions ( Stonier et al., 2013; Allmendinger et al., 2012, 2014a,b ). It
s also assumed that the realised values of each uncertain parame-
er remain the same in different batches ( Liu et al., 2016 ). 
The multi-objective optimisation problem addressed in this
ork can be described as follows: 
Given are: 
• manufacturing process of a mAb product; 
• upstream bioreactor titre; 
• candidate chromatography resins at each step, and their key
characteristics, e.g., yield, linear velocity, buffer usage, dynamic
binding capacity, and LRV of HCPs; 
• key characteristics of non-chromatography steps, e.g., yield,
time and buffer usage; 
• relevant cost data, e.g., reference equipment costs, labour wage,
resin, buffer and media prices; 
• candidate column diameters and heights, numbers of columns
and cycles; 
• probability distributions of titre, chromatography yields and
LRVs of HCPs; 
To determine: 
• chromatography sequencing strategies, i.e., resin at each chro-
matography step; 
• chromatography column sizing strategies, i.e., column diameter
and bed height, number of columns, and number of cycles per
batch at each chromatography step; 
• product mass and volume, and buffer usage volume; 
• number of total completed batches; 
• annual total processing time; 
So as to: 
inimise the COG/g and maximise the total LRV of the whole mAb
uriﬁcation process. 


























































































L  3. Mathematical formulation 
In this section, a CCP-based multi-objective optimisation model
for the optimal chromatography sequencing and sizing decisions is
presented, to deal with uncertainties in titre and chromatography
resin yields and LRVs of HCPs, based on the literature MILFP model
for DSP puriﬁcation process optimisation ( Liu et al., 2014 ), which is
given in the Supplementary Material. There are a large number of
constraints and variables for the modelling of the highly complex
process, including the product masses and volumes, buffer volumes
and processing times in downstream operations, the calculation of
relevant cost terms, and the linearisation the nonlinear constraints
in the proposed optimisation model. Only the newly developed
constraints in this work are presented in this section. 
The uncertain upstream titre, chromatography resin yields and
LRVs of HCPs are tackled using the classic CCP approach, in which
a risk tolerance is determined by the decision maker as a per-
missible probability of violation in the constraints involving uncer-
tain parameters ( Charnes and Cooper, 1959 ). The developed chance
constraints are transformed into their deterministic equivalent for-
mulations using the expression of the inverse cumulative distribu-
tion function. The chance constraints for three parameter sets in
the CCP approach are presented next in this section. 
3.1. Chance constraints for uncertain titre 
In the deterministic model, the initial protein mass from the
upstream processes in each batch, M 0 , is determined by the biore-
actor titre, titre , and the working volume of bioreactor: 
M 0 = t it re · α · brv (1)
where α is the working volume ratio of the bioreactor, and brv
is the volume of the single bioreactor, estimated by a rule-based
method ( Simaria et al., 2012; Liu et al., 2013a,b, 2016 ), as follows: 
brv = dem 
α · titre · maxbn · σ ·∏ s ∈ CS min 
r∈ R s 
cy sr ·
∏ 
s / ∈CS nc y s 
(2)
where dem is the target demand; maxbn is the maximum batches
allowed, determined by the number of bioreactors utilised; σ is
batch success rate; and cy sr and ncy s are the yields at chromatog-
raphy and non-chromatography steps, respectively. 
When the parameter, titre , becomes uncertain, to develop a
chance constraint to model uncertainty, Eq. (1) is ﬁrstly converted
into an inequality, as shown in Eq. (3) in which M 0 is upper-
bounded as it is maximised to achieve the minimum COG/g: 
M 0 ≤ t it re · α · brv (3)
The corresponding chance constraint is formulated by enforcing
the probability of the inequality above a certain limit, as follows:
Pr ( M 0 ≤ t it re · α · brv ) ≥ A t (4)
where A t is a minimum prespeciﬁed probability that Eq. (3) will
hold true, as conﬁdence level taking a value between 50% and
100%. 
The above Eq. (4) can be written using the probability of the
uncertain titre: 
1 − Pr 
(
t it re ≤ M 0 
α · brv 
)
≥ A t (5)
Here, the upstream titre is assumed to follow a triangular
probability distribution, Tr( titre l , titre p , titre u ), where titre l , titre p 
and titre u are lower bound, peak and upper bound, respectively.
Its cumulative distribution function is denoted as ( titre ). Thus,




α · brv 
)
≤ 1 − A t (6)Using the inverse cumulative distribution function expression,
he deterministic equivalent formulation of Eq. (3) is as follows: 
 0 ≤ −1 
(
1 − A t 
)
· α · brv (7)
For an isosceles triangular distribution where t it r e u − t it r e p =
 it r e p − t it r e l = t it re , −1 ( 1 − A t ) = t it r e l + 
√ 
2( 1 − A t ) · t it re , if
 
t > 50%. The peak can also be used to estimate the bioreactor vol-
me in Eq. (2) . 
.2. Chance constraints for uncertain yields 
The yield at a chromatography step links the product mass
mount in the inﬂow and outﬂow of the step, determined by the
elected resin’s yield: 
 s = 
∑ 
r∈ R s 
c y sr ·UM s −1 ,r , ∀ s ∈ CS (8)
here UM s −1 ,r is an auxiliary variable to represent U sr · M s −1 , in
hich U sr is a binary variable to indicate whether resin r is se-
ected at chromatography step s , and M s is the mAb mass of each
atch after step s . 
To model the uncertainty of resin yield, we introduce an uncer-
ain parameter, cyd s , to denote the deviation of the selected resin’s
ield from its standard value, cy sr , at chromatography step s . Thus,
e can convert the constraint involving the uncertainty of resin
ields into an inequality as follows: 
 s ≤
∑ 
r∈ R s 
c y sr ·UM s −1 ,r · cy d s , ∀ s ∈ CS (9)
Similarly, given a conﬁdence level of Eq. (9) being true for each
hromatography step s , A 
y 
s , its corresponding chance constraint can





r∈ R s 
c y sr ·UM s −1 ,r · cy d s 
) 
≥ A y s , ∀ s ∈ CS (10)
Here, the yield deviation, cyd s , is an uncertain parameter fol-
owing a triangular distribution, Tr ( cyd l s , cyd 
p 
s , cyd 
u 
s ) . The peak cyd 
p 
s 
s 100%, while cyd l s and cyd 
u 
s are lower and upper bounds of the
ield deviation at chromatography step s . The cumulative distribu-
ion function is denoted as ¯s ( cy d s ) . Thus, similar to the discus-
ion to titre in Section 3.1 , Eq. (10) can be reformulated as below:
 s ≤ ¯−1 s 
(




r∈ R s 
c y sr ·UM s −1 ,r , ∀ s ∈ CS (11)
here ¯−1 s ( 1 − A y s ) = cyd l s + 
√ 
2( 1 − A t ) · c y d s , if c yd u s − c yd p s =
yd 
p 
s − cyd l s = cy d s and A y s > 50% . 
.3. Chance constraints for uncertain LRVs 
To ensure the purity of the mAb product meets the target level
fter the puriﬁcation process, HCPs, one of the critical impurities,
ust be removed during the process. The capability to remove
CPs of each resin is measured in terms of LRV, lrv sr . Thus, the LRV
t each chromatography step is determined by the selected resin:
R V s = 
∑ 
r∈ R s 
lr v sr ·U sr , ∀ s ∈ CS (12)
To generate a chance constraint for uncertain LRV, Eq. (12) is
onverted into an inequality, with the introduction of an uncertain
arameter, lrvd s , to represent the deviation of the selected resin’s
RV from its standard value at chromatography step s, lrv sr : 
R V s ≤
∑ 
r∈ R s 
l r v sr ·U sr · l rv d s , ∀ s ∈ CS (13)




































































































d  here LRV s is restricted by an upper bound as it is aimed to be
aximised at each step. 
Similarly, the corresponding chance constraint of Eq. (13) with
 given conﬁdence level of its being valid, A l s , is as follows: 
r 
( 
LR V s ≤
∑ 
r∈ R s 
l r v sr ·U sr · l rv d s 
) 
≥ A l s , ∀ s ∈ CS (14)
The uncertain LRV deviation, lrvd s , also follows a triangular dis-
ribution, Tr ( l rv d l s , l rv d 
p 
s , l rv d u s ) , in which the peak, lrv d 
p 
s , is also
00%, and lrv d l s and lrv d u s are the corresponding lower and upper
ounds. Given its cumulative distribution, ˜ s ( lrv d s ) , we have the
ollowing deterministic equivalent formulation of Eq. (13) : 
R V s ≤ ˜ −1 s 
(




r∈ R s 
lr v sr ·U sr , ∀ s ∈ CS (15)
Here, under an isosceles triangular distribution where
 rv d u s − l rv d p s = l rv d p s − l rv d l s = l rv d s , we have ˜ −1 s ( 1 − A l s ) =
 rv d l s + 
√ 
2( 1 − A l s ) · l rv d s when A l s > 50% . 
.4. Objective functions 
This problem includes two objective functions to simultane-
usly consider both cost and impurity reduction ability of the pu-
iﬁcation process. The ﬁrst objective, COG/g, i.e., the ratio of the
otal COG, COG , to the annual production, AP , is minimised: 
in OB J 1 = COG 
AP 
(16) 
The second objective considers the maximisation of total impu-
ity removal capability, which is represented by total LRV of the
rocess, deﬁned as the summation of the LRVs at all three chro-
atography steps: 
ax OB J 2 = 
∑ 
s ∈ CS 
LR V s (17) 
Overall, the optimisation problem under uncertainty is for-
ulated as a CCP-based multi-objective optimisation model (de-
oted as MO –CCP) with chance constraints, Eqs. (7) , (11) , (15) , as
ell as other constraints, Eqs. (S.1)-(S.7), (S.9), (S.11)-(S.84) pro-
ided in the Supplementary Material, and Eqs. (16) and (17) as
he objective functions. When no uncertainty is considered, the
eterministic optimisation model (denoted as MO-DET) includes
qs. (12) , (S.1)-(S.84) in the Supplementary Material as constraints,
nd Eqs. (16) and (17) as the objective functions, which will be
ompared to the proposed MO –CCP model later in this work. 
. Solution approach 
To solve the proposed multi-objective optimisation model in
he above section, we adapt the classic ɛ -constraint method
 Haimes et al., 1971 ; Chankong and Haimes, 1983 ), where only one
bjective is optimised and all other objectives are converted into
onstraints by setting an upper or lower bound to each of them, to
chieve the minimum-cost solution under total LRV requirement.
he obtained solutions are proven to satisfy the Pareto optimality
 Miettinen, 1999 ). 
In the proposed multi-objective optimisation problem, between
he two objectives, the COG/g is kept as the objective function,
hile the total LRV of HCPs is transformed as a constraint lim-
ted by a lower bound. Thus, the multi-objective model MO-CCP is




 . t . 
∑ 
s ∈ CS 
LR V s ≥ T LR V min 
Eqs . ( 7 ) , ( 11 ) , ( 15 ) , ( S . 1 ) −( S . 7 ) , ( S . 9 ) , ( S . 11 ) −( S . 84 ) 
here TLRV min refers to the minimum required total LRV to ensure
hat the purity of ﬁnal products is higher than the given target pu-
ity level. By changing the value of TLRV min , a set of Pareto-optimal
olutions can be achieved. The above SO –CCP model solved in each
teration of ɛ -constraint method is an MILFP model. Similar to the
ork of Liu et al. (2014, 2015, 2018 ), the Dinkelbach’s algorithm
 Dinkelbach, 1967 ) is applied to the MILFP model by iteratively
olving a number of MILP models, MILP-CCP, deﬁned as follows: 
in COG − f · AP 
 . t . 
∑ 
s ∈ CS 
LR V s ≥ T LR V min 
Eqs . ( 7 ) , ( 11 ) , ( 15 ) , ( S . 1 ) −( S . 7 ) , ( S . 9 ) , ( S . 11 ) −( S . 84 ) 
here f is a parameter whose value is updated by iterations. 
Overall, the proposed iterative solution approach integrating
oth ɛ -constraint method and Dinkelbach’s algorithm is illustrated
n Fig. 2 . The proposed iterative solution procedure consists of
olving a number of CCP-based MILP models iteratively, result-
ng in a set of Pareto-optimal solutions of the developed multi-
bjective optimisation model under uncertainty, MO –CCP. Note
hat the similar procedure is also applicable to the deterministic
ulti-objective optimisation problem, MO-DET, by solving a collec-
ion of deterministic MILP models. 
. Case study 
In this section, an industrially-relevant example, based on a
Ab puriﬁcation process in a biopharmaceutical company, is intro-
uced to examine the applicability of the proposed models and ap-
roaches. There are 11 candidate commercial resins in two modes,
inding-elution (BE) and ﬂow-through (FT) and the following ﬁve
ypes: 
• aﬃnity chromatography (AFF); 
• cation-exchange chromatography (CEX 
• anion-exchange chromatography (AEX); 
• mixed-mode chromatography (MM); 
• hydrophobic interaction chromatography (HIC). 
The characteristics of these resin candidates are shown in
able 1 , where the standard values of yield and LRV of each resin
re shown, and their actual values during production may vary
rom those. 
As to the chromatography column sizing decisions, 11 discrete
otential bed heights and 10 discrete potential diameters are avail-
ble for selection, as shown in Table 2 . There also could be up to
 parallel columns utilised at each chromatography step and each
atch could run in at most 10 cycles. 
Here, multiple USP trains could be used to feed one DSP train.
ccording to the previous work ( Liu et al., 2013a,b, 2014, 2015,
016, 2017 ), single bioreactor has higher cost eﬃciency than other
ases. Therefore, only one bioreactor is considered in this case
tudy, while multiple bioreactors can be easily accommodated into
he proposed models. Considering a target demand of 500 kg, the
olume of the single bioreactor can be calculated using Eq. (2) ,
hich is 25,017 L. More data in the case study are given in the
upplementary Material (Tables S1-S3). The three uncertain param-
ters considered in this work all follow isosceles triangular prob-
bility distributions, as described in Table 3 . It is assumed that
ifferent chromatography steps use the same distribution function
onsidering uncertain yield and LRV deviation. 
388 S. Liu, L.G. Papageorgiou / Computers and Chemical Engineering 119 (2018) 383–393 
Fig. 2. The proposed iterative solution approach of the proposed MO –CCP model. 
Table 1 
Characteristics of resin candidates. 


















Standard yield Standard LRV of HCPs 
Cap. Int. Pol. Cap. Int. Pol. 
R1 AFF BE 50 2.3 37 150 100 9200 91% 95% - 3 1.5 - 
R2 AFF BE 30 2.3 37 300 100 6400 91% 95% - 3 1.5 - 
R3 AFF BE 50 2.3 37 800 100 9900 91% 95% - 3 1.5 - 
R4 AFF BE 30 2.3 37 10 0 0 100 90 0 0 91% 95% - 3 1.5 - 
R5 CEX BE 120 1.4 26 500 100 2500 86% - - 2 - - 
R6 CEX BE 40 1.4 26 300 100 400 86% 92% 92% 2 1 0.5 
R7 AEX FT 100 0 10 300 100 700 - 95% 95% - 0.5 0.3 
R8 MM FT 150 0 10 375 100 3500 - 90% 90% - 1.2 0.6 
R9 MM BE 50 1.4 26 100 100 1900 - 90% 90% - 1.5 0.8 
R10 MM BE 35 1.4 26 250 12 2700 - 90% 90% - 2 1 
R11 HIC BE 27.5 1.4 26 175 100 2500 - 89% 89% - 2 0.5 
Table 2 
Chromatography column size candidates. 
Decision Candidate values 
Bed height (cm) 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 
Diameter (cm) 50, 60, 70, 80, 90, 100, 120, 160, 180, 200 
Number of cycles 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 
Number of columns 1, 2, 3, 4 
Table 3 
Triangular probability distributions of uncertainty parameters. 
Parameter Lower bound Peak Upper bound 
titre 2 (g/L) 3 (g/L) 4 (g/L) 
cyd s 95% 100% 105% 








































D  6. Results and discussion 
In this section, the proposed optimisation model and solution
approach are applied to the above case study. Then, the obtained
optimal manufacturing strategies are examined through Monte
Carlo (MC) simulation. At last, the sensitivity analysis of conﬁdence
level is conducted. All computational runs were implemented in
GAMS 24.7 ( GAMS Development Cooperation, 2016 ) on a 64-bit
Windows 7 based machine with Intel Core i5-3330 3.00 GHz pro-
cessor and 8.0 GB RAM, using CPLEX as MILP solver. 
6.1. Optimal results 
The proposed multi-objective optimisation model, MO –CCP, as
well as the deterministic model, MO-DET, as the base case for com-arison, are solved. The conﬁdence level of chance constraint feasi-
ility in the MO –CCP model is set to 95%, i.e., A t = A y s = A l s = 95% .
ith a 95% conﬁdence level, −1 ( 1 − A t ) in Eq. (7) , ¯−1 s ( 1 − A y s )
n Eq. (11) and ˜ −1 s ( 1 − A l s ) in Eq. (15) are approximately equal to
.32, 96.58%, and 86.32%, respectively. 
To implement the proposed solution approach, the minimum
otal LRV requirement of the puriﬁcation process is initially set
o 3.4 g/L, and then is gradually increased to 5 g/L ( TLRV U ) with a
tep of 0.2 g/L ( TLRV ), and therefore a Pareto curve consisting of
 Pareto-optimal solutions is obtained. The Pareto frontier of the
O –CCP model is compared with that of the MO-DET model in
ig. 3 , where the optimal chromatography sequence of each Pareto-
ptimal solution is also presented. Table 4 shows the optimal chro-
atography column sizing decisions under each minimum total
RV requirement. 
Firstly, the optimal chromatography decisions of the MO-DET
roblem are focused on. R5 (CEX) is selected at the capture step
hen the minimum required total LRV is low ( < 4), but R3 (AFF)
ith a higher standard LRV (3) is chosen when the minimum re-
uired total LRV increases, even it is much more expensive than
5. Meanwhile, R7 (AEX) is used for polishing at all optimal solu-
ions. The actual total standard LRV of the whole process increases
rom 3.5 to 5.3, to meet the impurity removal capability require-
ent. As to the chromatography column sizing decisions, only one
hromatography column is used at all steps in all solutions, while
he other decisions vary, except that only the column with a diam-
ter of 100 cm is always used at the capture step. With increas-
ng minimum required total LRVs, COG/g increases by 10% from
68.4/g to £75.2/g. 
Next, by comparing the solutions of MO –CCP to those of MO-
ET, it can be seen that, for each minimum required total LRV,
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Fig. 3. The optimal COG/g and chromatography sequences of the MO –CCP and MO-DET models. 
Table 4 
Pareto-optimal solutions of the MO –CCP and MO-DET models. 
Minimum total LRV Total standard LRV COG/g (£/g) Column diameter ∗ (cm) Column bed height ∗ (cm) No. of columns ∗ No. of cycles per batch ∗
Model MO-DET 3.4 3.5 68.4 100/50/70 15/15/17 1/1/1 4/10/6 
3.6 3.8 69.6 100/90/70 20/23/18 1/1/1 3/6/6 
3.8 3.8 69.6 100/90/70 20/23/18 1/1/1 3/6/6 
4.0 4.3 70.3 100/120/70 18/17/16 1/1/1 8/6/7 
4.2 4.3 70.3 100/120/70 18/17/16 1/1/1 8/6/7 
4.4 4.5 70.7 100/70/80 24/20/21 1/1/1 6/4/4 
4.6 4.8 72.5 100/160/60 18/23/21 1/1/1 8/2/7 
4.8 4.8 72.5 100/160/60 18/23/21 1/1/1 8/2/7 
5.0 5.3 75.2 100/180/70 16/22/18 1/1/1 9/3/6 
Model MO –CCP 3.4 4.3 97.9 100/120/60 16/19/22 1/1/1 7/4/5 
3.6 4.3 97.9 100/120/60 16/19/22 1/1/1 7/4/5 
3.8 4.5 98.9 90/70/80 23/20/20 1/1/1 6/3/3 
4.0 4.8 100.9 10 0/20 0/60 16/22/18 1/1/1 7/1/6 
4.2 5.3 104.1 100/160/60 16/21/21 1/1/1 7/3/5 
4.4 5.3 104.1 100/160/60 16/21/21 1/1/1 7/3/5 
4.6 5.5 109.1 100/160/100 16/21/19 1/1/1 7/3/5 
4.8 5.6 110.1 100/160/50 16/21/17 1/1/1 7/3/6 
5.0 5.8 112.3 100/160/160 16/21/15 1/1/1 7/3/2 
∗ values at capture/intermediate puriﬁcation/polishing chromatography steps 
Fig. 4. Average COG/g in MC simulation on the solutions of the MO –CCP (95% conﬁdence level) and MO-DET models. 
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Fig. 5. Mean total LRVs and probabilities of failing to meet LRV requirement in MC simulation on the solutions of the MO –CCP (95% conﬁdence level) and MO-DET models. 

































(  the MO –CCP model usually chooses a different chromatography se-
quence with higher total standard LRV than that of MO-DET model.
For example, when the minimum required total LRV is 3.8, the
MO –CCP model chooses a sequence of R3-R8-R7, which has a total
standard LRV of 4.5, in order to guarantee that the realised total
LRV is no less than the required level at the given conﬁdence level
(95%), while the optimal sequence of the MO-DET model, R5-R3-
R7, has a total LRV of 3.8 only, which will fail to meet the require-
ment if the realisation is below expectation. Comparing the total
standard LRVs in the solutions of two models, the sequence of the
MO –CCP model is averagely 0.7 higher than that of the MO-DET
model, and 0.8 higher than the minimum required total LRV. More-
over, the selected sequence of the MO –CCP model is also more ex-
pensive. Different from the solutions of MO-DET model, R5 is no
longer a choice at the capture step, while R3 is used no matter
whether the total LRV requirement is low or high. However, at the
polishing step, although R7 (AEX) with relatively lower price and
t  RV is chosen in most cases, resins having higher LRVs are used
hen the impurity removal capability requirement increases. Due
o the chance constraints on titre and yields, the selected column
izes of the MO –CCP model is smaller than the MO-DET model,
eading to lower production. Similar to the deterministic case, the
OG/g increases with increasing minimum required total LRV. Due
o the higher cost and lower production, the obtained COG/g by
ptimising the MO –CCP model is over 40% higher than the MO-
ET model. In the next section, we will conduct an analysis of
C simulation to highlight the beneﬁts of the proposed CCP-based
odel. 
.2. MC simulation 
Here, a stochastic analysis is conducted to examine the im-
act of variability on the solutions by implementing MC simulation
 Kroese et al., 2011 ). MC simulation analysis was implemented on
he solutions obtained by both MO –CCP and MO-DET models. After
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q  btaining the optimal solutions of optimisation models, MC simu-
ation analysis was conducted by solving the deterministic optimi-
ation model, SO-DET, with ﬁxed design variables, including vari-
bles for chromatography sequence, column volume and number of
olumns, to re-optimise all other operational variables, dependent
n different realisations of uncertain parameters, titre, cyd s and
rvd s . In the proposed MC simulation, a total of 10 0 0 simulation
uns is implemented for each Pareto-optimal solution. Here, for
he random realisation of each simulation run, it is ﬁrstly checked
hether the realised total LRV meet the minimum required to-
al LRV. If the realised total LRV is less the minimum required
otal LRV, the single objective optimisation model subject to the
inimum required total LRV constraint is infeasible, and the ﬁnal
roduct of the generated puriﬁcation process cannot meet the tar-
et purity level, which is treated as wastes. In this case, we take
10 0 0/g as COG/g of this simulation run ( Liu et al., 2016 ), which
an be considered as the cost of outsourcing purchase. Otherwise,
hen the realised total LRV is no less than the minimum required
otal LRV, we run the deterministic model, SO-DET, to minimise
he COG/g subject to the minimum total LRV and other constraints.
he performance of the MC analysis is examined using the mean
OG/g in all simulation runs, which mimics the expected value of
OG/g. In addition, the probability of failing to meet the minimum
RV requirement is examined for the robustness of the selected
hromatography strategies. The procedure of MC simulation is de-
cribed as follows: 
P 1. Fix the optimal chromatography sequences, 
column volumes and the number of columns 
obtained from the optimisation models; P 2. Generate random titre, yield deviations 
and LRV deviations, all following 
triangular probability distributions as 
given in Table 4 ; 
P 3. If the total LRV is lower than the minimum 
required total LRV, COG/g is set to 1000; 
Otherwise, solve the model SO-DET with the 
random parameters by the proposed solution 
approach in Section 4 to obtain the optimal
COG/g; 
P 4. Go to Steps 2 and 3 and repeat for 1000 
times. 
Fig. 4 shows the mean values of COG/g in the MC simulation.
he mean values of COG/g in the MC simulation on the solutions
f the MO –CCP model vary between £70/g and £90/g, which are
ower than the optimal COG/g returned by the MO –CCP model,
ue to the underestimation of realisation of uncertain parame-
ers in the chance constraints. Meanwhile, the mean values of
OG/g in the MC simulation on the solutions of the MO-DET model
re signiﬁcantly higher by one order of magnitude, up to £560/g.
ig. 5 shows another beneﬁt of the solutions MO –CCP model. The
ean values of total LRV in the simulation on both MO –CCP and
O-DET models’ solutions are same as the total standard LRVs ob-
ained by the optimisation models, as reported in Table 4 , which
re all no less than the corresponding minimum required total
RVs. For the MO-DET model, the mean total LRV from the sim-
lation is not signiﬁcantly higher than the minimum required total
RV, with a difference of 0.3 at most and 0.1 on average. There-
ore, the realised total LRV has a lower chance to meet the LRV re-
uirement. For 9 Pareto-optimal solutions, the probabilities of total














































































































 LRV being lower than requirement are all greater than 10%, and the
probabilities for two solutions are even more than 50% when the
mean total LRV is the same as the minimum required value (3.8
and 4.8). In the meantime, the solutions of MO –CCP model obtain
chromatography sequences with much higher total LRVs, at least
16% higher than the required values. Thus, there are just few sim-
ulation runs whose realised total LRV is less than the minimum
required total LRV, and the probability of failing to meet the re-
quirement is 0% except for two solutions. When the minimum re-
quired total LRV is high (4.8 and 5), only 1 or 2 simulation runs
out of 10 0 0 cannot meet the requirement. The relatively higher to-
tal LRV and lower probability of not meeting required purity level
lead to the advantage of the solutions of the MO –CCP model. With
smaller COG/g and lower failure rates, the MO –CCP model shows
higher robustness, compared to the MO-DET model, to deal with
the uncertainties in titre, resin yield and impurity removal capa-
bility. 
Overall, the proposed MO –CCP model is able to cope with the
uncertainties of the parameters, i.e., titre, resin yields and LRVs in
this problem, to achieve signiﬁcant economic beneﬁts than the de-
terministic counterpart. 
6.3. Sensitivity analysis of conﬁdence levels 
In the proposed CCP-based model, the conﬁdence levels in the
chance constraints impact the probabilities of the solutions be-
ing feasible. A risk-averse decision with a higher conﬁdence level
makes the chance constraint to be held with higher probability.
Here, it is assumed that the same conﬁdence level is implemented
in all chance constraints. Three different conﬁdence levels, 90%,
95% and 98%, are considered in this section. The optimal solutions
obtained by the proposed MO –CCP model are examined using the
MC simulation as described in the previous section. The details
of the obtained optimal solutions with the 90% and 98% conﬁ-
dence levels are provided in the Supplementary Material (Tables
S4 and S5). In order to cope with low LRV realisation, the optimal
solutions with higher conﬁdence levels select chromatography se-
quences with higher total LRV, which are also more expensive, and
incur lower probabilities of being lower than the requirement, as
shown in Fig. 6 . When the conﬁdence level is 90%, the total LRVs of
the chromatography sequence in the optimal solutions are smaller
than the other two, and there are 6 solutions (out of 9) whose
simulation runs cannot meet total LRV requirement, although the
probability is quite low, only up to 2.5%. For the conﬁdence level
of 98%, the selected sequences have the highest total LRVs, and the
simulation runs of all solutions generate higher total LRVs than the
minimum requirement. 
Consequently, as presented in Fig. 7 , a conﬁdence level of 90%
achieves higher mean COG/g than the other two, except when the
minimum required total LRV is 5, much more expensive resins
are selected under the conference level of 98%, resulting in higher
COG/g. The COG/g in the simulation under the conference levels
of 95% and 98% are comparable to each other. It can be observed
that the achieved mean values are quite similar. When the mini-
mum required total LRVs are high (4.8 and 5), the conﬁdence level
of 95% gets slightly smaller mean COG/g than the conference level
of 98%, but has higher chance not to meet the minimum total LRV
requirement. Especiﬁcally for this problem, conﬁdence levels rang-
ing from 95% to 98% are applicable to chance constraints for high
quality solutions. 
7. Concluding remarks 
This work addressed the multi-objective optimisation of down-
stream processing of mAb products, to ﬁnd the optimal chromatog-
raphy sequencing and column sizing strategies. Both cost and im-urity removal capability of the puriﬁcation process are considered
s objectives. Considering uncertainties in bioreactor titre, chro-
atography yield and LRV of HCPs, a stochastic CCP-based multi-
bjective optimisation model has been developed by extending
revious work ( Liu et al., 2014 ). To solve the proposed model, ε-
onstraint method and Dinkelbach’s algorithm have been adapted
o develop an iterative solution approach to generate a set of
areto-optimal solutions with different minimum required total
RVs of the whole process. An industrially-relevant example has
een investigated. The computational results of 9 Pareto-optimal
olutions have shown that the CCP-based model deals with the
ariability of uncertain parameters in a better manner than the
eterministic model, through the valuation of MC simulation, ob-
aining much less mean COG/g. Also, a sensitivity analysis on the
onﬁdence level shows the effects on the selected resin LRVs and
OG/g in the MC simulation. 
cknowledgements 
Funding from the UK Engineering & Physical Sciences Research
ouncil ( EP/I033270/1 and EP/M027856/1 ) is gratefully acknowl-
dged. 
upplementary material 
Supplementary material associated with this article can be
ound, in the online version, at 10.1016/j.compchemeng.2018.09.015
eferences 
llmendinger, R. , Simaria, A.S. , Farid, S.S. , 2012. Eﬃcient discovery of chromatogra-
phy equipment sizing strategies for antibody puriﬁcation processes using evo-
lutionary computing. In: Parallel Problem Solving in Nature - PPSN XII. Lecture
Notes in Computer Science, vol. 7492. Berlin. Springer, pp. 468–477 . 
Allmendinger, R. , Simaria, A.S. , Farid, S.S. , 2014a. Closed-loop optimization of
chromatography column sizing strategies in biopharmaceutical manufacture. J.
Chem. Technol. Biotechnol. 89, 1481–1490 . 
llmendinger, R. , Simaria, A.S. , Farid, S.S. , 2014b. Multiobjective evolutionary opti-
mization in antibody puriﬁcation process design. Biochem. Eng. J. 91, 250–264 . 
runet, R. , Guillén-Gosálbez, G. , Pérez-Correa, J.R. , Caballero, J.A. , Jiménez, L. , 2012.
Hybrid simulation-optimization based approach for the optimal design of sin-
gle-product biotechnological processes. Comput. Chem. Eng. 37, 125–135 . 
Charnes, A. , Cooper, W.W. , 1959. Chance-constrained programming. Manag. Sci. 6,
73–79 . 
Chankong, V. , Haimes, Y.Y. , 1983. Multiobjective Decision Making: Theory and
Methodology. Elsevier Science, New York . 
inkelbach, W. , 1967. On nonlinear fractional programming. Manag. Sci. 13,
4 92–4 98 . 
GAMS Development Cooperation, 2016. GAMS: A User’s Guide. GAMS Development
Cooperation, Washington D.C. . 
Haimes, Y.Y. , Lasdon, L.S. , Wismer, D.A. , 1971. On a bicriterion formulation of the
problems of integrated system identiﬁcation and system optimization. IEEE
Trans. Syst. Man Cybern. 1, 296–297 . 
assan, S. , Simaria, A.S. , Varadaraju, H. , Gupta, S. , Warren, K. , Farid, S.S. , 2015. Al-
logeneic cell therapy bioprocess economics and optimization: downstream pro-
cessing decisions. Regen. Med. 10, 591–609 . 
roese, D.P. , Taimre, T. , Botev, Z.I. , 2011. Handbook of Monte Carlo Methods. John
Wiley & Sons, New Jersey . 
evine, H.L. , Cooney, B.R. , 2017. The Development of Therapeutic Monoclonal Anti-
body Products, 2nd Edition BioProcess Technology Consultants, Inc. . 
evy, N.E. , Valente, K.N. , Choe, L.H. , Lee, K.H. , Lenhoff, A.M. , 2014. Identiﬁcation
and characterization of host cell protein product-associated impurities in mon-
oclonal antibody bioprocessing. Biotechnol. Bioeng. 111, 904–912 . 
iu, S. , Farid, S.S. , Papageorgiou, L.G. , 2016. Integrated optimization of upstream
and downstream processing in biopharmaceutical manufacturing under uncer-
tainty: a chance constrained programming approach. Ind. Eng. Chem. Res. 55,
4599–4612 . 
iu, S. , Gerontas, S. , Gruber, D. , Turner, R. , Titchener-Hooker, N.J. , Papageorgiou, L.G. ,
2017. Optimization-based framework for resin selection strategies in biophar-
maceutical puriﬁcation process development. Biotechnol. Prog. 33, 1116–1126 . 
iu, S. , Papageorgiou, L.G. , 2018. Optimal production of biopharmaceutical manufac-
turing. In: Singh, R., Yuan, Z. (Eds.). In: Process Systems Engineering for Pharma-
ceutical Manufacturing. Computer Aided Chemical Engineering, Vol. 41. Elsevier,
Amsterdam, pp. 569–595 . 
iu, S. , Simaria, A.S. , Farid, S.S. , Papageorgiou, L.G. , 2013a. Mixed integer optimi-
sation of antibody puriﬁcation processes. In: Kraslawski, A., Turunen, I. (Eds.),






























V  Proceedings of the 23rd European Symposium on Computer Aided Process En-
gineering, Computer Aided Chemical Engineering, Vol. 32. Amsterdam. Elsevier,
pp. 157–162 . 
iu, S. , Simaria, A.S. , Farid, S.S. , Papageorgiou, L.G. , 2013b. Designing cost-effective
biopharmaceutical facilities using mixed-integer optimization. Biotechnol. Prog.
29, 1472–1483 . 
iu, S. , Simaria, A.S. , Farid, S.S. , Papageorgiou, L.G. , 2014. Optimising chromatography
strategies of antibody puriﬁcation processes by mixed integer fractional pro-
gramming techniques. Comput. Chem. Eng. 68, 151–164 . 
iu, S. , Simaria, A.S. , Farid, S.S. , Papageorgiou, L.G. , 2015. Mathematical program-
ming approaches for downstream processing optimisation of biopharmaceuti-
cals. Chem. Eng. Res. Des. 94, 18–31 . 
iu, Y. , Gunawan, R. , 2017. Bioprocess optimization under uncertainty using ensem-
ble modeling. J. Biotechnol. 244, 34–44 . 
artagan, T. , Krishnamurthy, A . , Leland, P.A . , Maravelias, C.T. , 2018. Performance
guarantees and optimal puriﬁcation decisions for engineered proteins. Oper.
Res. 66, 18–41 . 
artagan, T. , Krishnamurthy, A. , Maravelias, C.T. , 2016. Optimal condition-based har-
vesting policies for biomanufacturing operations with failure risks. IIE Trans. 48,
440–461 . 
iettinen, K. , 1999. Nonlinear Multiobjective Optimization. Kluwer Academic Pub-
lishers, Norwell . 
atali, J.M. , Pinto, J.M. , Papageorgiou, L.G. , 2009. Eﬃcient MILP formulations for the
simultaneous optimal peptide tag design and downstream processing synthesis.
AIChE J. 55, 2303–2317 . irrung, S.M. , van der Wielen, L.A. , van Beckhoven, R.F. , van de Sandt, E.J. , Ep-
pink, M.H. , Ottens, M. , 2017. Optimization of biopharmaceutical downstream
processes supported by mechanistic models and artiﬁcial neural networks.
Biotechnol. Prog. 33, 696–707 . 
olykarpou, E.M. , Dalby, P.A. , Papageorgiou, L.G. , 2011. Optimal synthesis of chro-
matographic trains for downstream protein processing. Biotechnol. Prog. 27,
1653–1660 . 
imaria, A.S. , Hassan, S. , Varadaraju, H. , Rowley, J. , Warren, K. , Vanek, P. , Farid, S.S. ,
2014. Allogeneic cell therapy bioprocess economics and optimization: single-use
cell expansion technologies. Biotechnol. Bioeng. 111, 69–83 . 
imaria, A.S. , Turner, R. , Farid, S.S. , 2012. A multi-level meta-heuristic algorithm
for the optimisation of antibody puriﬁcation processes. Biochem. Eng. J. 69,
144–154 . 
imeonidis, E. , Pinto, J.M. , Lienqueo, M.E. , Tsoka, S. , Papageorgiou, L.G. , 2005. MINLP
models for the synthesis of optimal peptide tags and downstream protein pro-
cessing. Biotechnol. Prog. 21, 875–884 . 
tonier, A. , Pain, D. , Westlake, A. , Hutchinson, N. , Thornhill, N.F. , Farid, S.S. , 2013. In-
tegration of stochastic simulation with multivariate analysis: short-term facility
ﬁt prediction. Biotechnol. Prog. 29, 368–377 . 
asquez-Alvarez, E. , Lienqueo, M.E. , Pinto, J.M. , 2001. Optimal synthesis of protein
puriﬁcation processes. Biotechnol. Prog. 17, 685–696 . 
